Form 4: CytoDyn Director Stephen Simes Receives Stock Options as Part of Annual Grant
SEC Form 4 Filing
Stephen Simes, a director at CytoDyn Inc., was granted stock options for 800,000 shares as part of his annual compensation for fiscal year 2025.
Summary
- Stephen Simes, a director of CytoDyn Inc., filed a Form 4 on October 30, 2024, reporting a transaction that occurred on October 28, 2024.
- The transaction involved the grant of non-qualified stock options for 800,000 shares of CytoDyn's common stock.
- The exercise price of these options is $0.13 per share, and they expire on October 28, 2034.
- 266,664 shares vested immediately on the grant date, with the remaining shares vesting in equal monthly installments from October 2024 through May 2025.
- Simes also has a Limited Power of Attorney appointing Jacob Lalezari, Mitchell Cohen, Tyler Blok, and Nathan Fox to act on his behalf for SEC filings related to CytoDyn securities.
Sentiment
Score: 6
Explanation: The document is a routine disclosure of a stock option grant, which is neither particularly positive nor negative. It's a standard part of executive compensation.
Positives
- The granting of stock options aligns the director's interests with those of the shareholders.
- The vesting schedule encourages continued service and contribution to the company.
Future Outlook
The remaining stock options will vest in equal monthly installments from October 2024 through May 2025, contingent upon continued service.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a typical component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
- The vesting schedule, with a portion vesting immediately and the remainder vesting over time, is also a common practice to incentivize long-term commitment.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
Stakeholder Impact
- Shareholders may view the stock option grant as a way to align the director's interests with the company's long-term success.
- The grant has a dilutive effect on existing shareholders, although this is a standard consideration with equity-based compensation.
Key Dates
| Date | Description |
|---|---|
| February 1, 2024 | Effective date of the Limited Power of Attorney. |
| October 28, 2024 | Date of the stock option grant and initial vesting of 266,664 shares. |
| October 30, 2024 | Date the Form 4 was filed. |
| October 28, 2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.